Product Datasheet
XEDAR Antibody
Catalog Number: 24427
Technical:tech@swbio.com
Information:info@swbio.com
Description
- Swiss-Prot No.:
- Swiss-Prot:Q9HAV5
Gene ID:60401
- Form of Antibody:
- Supplied in PBS containing 0.02% sodium azide.
- Storage:
- Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
- Immunogen:
- Raised against recombinant human XEDAR.
- other_names:
- X-linked ectodysplasin-A2 receptor, EDA-A2 receptor, TNFRSF27
- Purification:
- Affinity chromatography purified via peptide column
- Applications:
- ELISA WB IHC
- Background:
- X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κB and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.
© Signalway Biotechnology All Rights Reserved.